{
    "ticker": "RLMD",
    "name": "Relmada Therapeutics, Inc.",
    "description": "Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel therapies for the treatment of pain and related conditions. Founded in 2011 and headquartered in New York City, Relmada is committed to addressing the unmet medical needs of patients suffering from chronic pain, utilizing its proprietary drug development platform. The company's lead product candidate, RL-817, is an innovative oral formulation designed to provide effective pain relief with a favorable safety profile. Relmada is also developing other product candidates targeting various pain conditions, including neuropathic pain and fibromyalgia. By leveraging advanced drug delivery technologies and a deep understanding of the mechanisms of pain, Relmada aims to create treatments that can significantly improve patients' quality of life while minimizing the risks associated with traditional pain management therapies, such as opioids. The company is dedicated to advancing its pipeline through rigorous clinical trials and collaborations with leading research institutions. Relmada's mission is to transform the landscape of pain management and provide patients with safer, more effective treatment options.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2011",
    "website": "https://www.relmada.com",
    "ceo": "Santiago E. Restrepo",
    "social_media": {
        "twitter": "https://twitter.com/Relmada",
        "linkedin": "https://www.linkedin.com/company/relmada-therapeutics/"
    },
    "investor_relations": "https://ir.relmada.com",
    "key_executives": [
        {
            "name": "Santiago E. Restrepo",
            "position": "CEO"
        },
        {
            "name": "Lorenzo A. B. G. Torres",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pain Management",
            "products": [
                "RL-817",
                "RL-371"
            ]
        }
    ],
    "seo": {
        "meta_title": "Relmada Therapeutics, Inc. | Innovative Pain Management Solutions",
        "meta_description": "Explore Relmada Therapeutics, Inc., a biotech company focused on developing novel therapies for pain management. Discover their innovative pipeline and commitment to patient care.",
        "keywords": [
            "Relmada Therapeutics",
            "Chronic Pain",
            "Biotechnology",
            "Pain Management",
            "RL-817",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is Relmada Therapeutics known for?",
            "answer": "Relmada Therapeutics is known for developing novel therapies aimed at treating chronic pain and related conditions."
        },
        {
            "question": "Who is the CEO of Relmada Therapeutics?",
            "answer": "Santiago E. Restrepo is the CEO of Relmada Therapeutics, Inc."
        },
        {
            "question": "Where is Relmada Therapeutics headquartered?",
            "answer": "Relmada Therapeutics is headquartered in New York City, New York, USA."
        },
        {
            "question": "What are Relmada's main products?",
            "answer": "Relmada's main products include RL-817 and RL-371, which are aimed at pain management."
        },
        {
            "question": "When was Relmada Therapeutics founded?",
            "answer": "Relmada Therapeutics was founded in 2011."
        }
    ],
    "competitors": [
        "AMRN",
        "GWPH",
        "NVCR",
        "ZGNX"
    ],
    "related_stocks": [
        "VRTX",
        "SRPT",
        "BMRN",
        "CLVS"
    ]
}